5
Ahlcon Parenterals
524448 BSE
Ahlcon Parenterals
Healthcare BSE: 524448 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.35% over past five years.
Growth Rate
Revenue Growth
4% lower than
3Y
Net Income Growth
-9%
Quarterly Results
| Particulars | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|
| Sales | 30.34 | 28.74 | 29.46 | 30.62 | 31.15 | 28.4 | 28.24 | 33.2 |
| Expenses | 21.96 | 20.25 | 21.83 | 22.11 | 21.01 | 21.84 | 23.41 | 24.58 |
| Operating Profit | 8.38 | 8.49 | 7.63 | 8.51 | 10.14 | 6.56 | 4.83 | 8.62 |
| OPM % | 27.62% | 29.54% | 25.9% | 27.79% | 32.55% | 23.1% | 17.1% | 25.96% |
| Other Income | 0.01 | 0.19 | 0.09 | -0.02 | 0.03 | 0.08 | 0.23 | 0.26 |
| Interest | 0.65 | 0.51 | 0.5 | 0.38 | 0.19 | 0.05 | 0.11 | 0.07 |
| Depreciation | 0.91 | 0.87 | 0.85 | 0.87 | 0.85 | 1.09 | 1.09 | 1.08 |
| PBT | 6.83 | 7.3 | 6.37 | 7.24 | 9.13 | 5.5 | 3.86 | 7.73 |
| Tax % | 33.67% | 31.23% | 41.13% | 35.22% | 33.95% | 29.27% | 26.94% | 15.27% |
| Net Profit | 4.53 | 5.02 | 3.75 | 4.69 | 6.03 | 3.89 | 2.82 | 6.55 |
| EPS in Rs | 6.29 | 6.97 | 5.21 | 6.51 | 8.37 | 5.4 | 3.92 | 9.1 |
Profit & Loss
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 38 | 50 | 62 | 79 | 108 | 120 | 116 | 118 | 135 | 150 | 156 |
| Expenses | 33 | 31 | 36 | 51 | 66 | 83 | 85 | 90 | 110 | 116 | 131 | 144 |
| Operating Profit | 13 | 7 | 15 | 11 | 13 | 25 | 35 | 26 | 9 | 19 | 19 | 12 |
| OPM % | 29% | 17% | 29% | 18% | 17% | 23% | 29% | 22% | 7% | 14% | 13% | 8% |
| Other Income | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 4 | 2 |
| Interest | 2 | 2 | 2 | 2 | 4 | 3 | 2 | 1 | 17 | 17 | 27 | 28 |
| Depreciation | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 5 | 16 | 16 | 39 | 33 |
| PBT | 10 | 3 | 11 | 6 | 7 | 19 | 30 | 21 | -24 | -14 | -43 | -48 |
| Tax % | 38% | 34% | 35% | 34% | 31% | 31% | 35% | 19% | -22% | 0% | 0% | 0% |
| Net Profit | 6 | 2 | 7 | 4 | 5 | 13 | 20 | 17 | -19 | -14 | -43 | -48 |
| EPS in Rs | 8.51 | 3.14 | 9.94 | 5.96 | 6.94 | 17.87 | 27.08 | 23.64 | -25.74 | -19.19 | -60.3 | -66.07 |
| Div. Payout % | 18% | 48% | 15% | 25% | 14% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves | 20 | 21 | 27 | 30 | 34 | 47 | 66 | 83 | 64 | 50 | 7 | -41 |
| Borrowings | 19 | 14 | 11 | 26 | 24 | 18 | 43 | 206 | 251 | 274 | 289 | 296 |
| Other Liabilities | 13 | 10 | 14 | 18 | 18 | 23 | 26 | 43 | 37 | 33 | 23 | 53 |
| Total Liabilities | 60 | 53 | 59 | 81 | 83 | 96 | 143 | 339 | 359 | 364 | 326 | 315 |
| Fixed Assets | 37 | 35 | 35 | 50 | 50 | 46 | 50 | 278 | 289 | 275 | 268 | 246 |
| CWIP | 2 | 2 | 3 | 2 | 3 | 8 | 26 | 3 | 11 | 27 | 4 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 20 | 15 | 21 | 28 | 30 | 41 | 67 | 58 | 59 | 61 | 54 | 67 |
| Total Assets | 60 | 53 | 59 | 81 | 83 | 96 | 143 | 339 | 359 | 364 | 326 | 315 |
Cash Flow
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 7 | 6 | 9 | — | — | — | — | — | — | — | — | — |
| Investing | -12 | 0 | -2 | — | — | — | — | — | — | — | — | — |
| Financing | 5 | -6 | -4 | — | — | — | — | — | — | — | — | — |
| Net Cash Flow | 0 | -1 | 2 | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -5 | 6 | 7 | — | — | — | — | — | — | — | — | — |
| CFO/OP | 74 | 110 | 85 | — | — | — | — | — | — | — | — | — |
Ratios
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 73 | 79 | 85 | 60 | 87 | 102 | 99 | 81 | 90 | 62 | 67 |
| Inventory Days | 186 | 118 | 112 | 120 | 124 | 96 | 73 | 125 | 197 | 140 | 127 | 181 |
| Days Payable | 131 | 49 | 96 | 88 | 83 | 76 | 74 | 67 | 57 | 33 | 102 | 94 |
| Cash Conversion Cycle | 114 | 142 | 95 | 117 | 101 | 107 | 100 | 156 | 221 | 198 | 86 | 153 |
| Working Capital Days | 79 | 84 | 68 | 78 | 65 | 76 | 78 | 54 | 53 | 68 | 65 | 52 |
| ROCE % | 28% | 12% | 29% | 17% | 17% | 32% | 34% | 10% | -2% | 1% | -5% | -7% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ahlcon Parenterals insights
60 extracted metrics + investor summaries across FY08–FY19.
Documents
1
Board Meeting Outcome for Outcome Of Board Meeting Held On 28Th January, 2026
28 Jan - Board approved Q3/9M FY26 unaudited results; exceptional labour-code charge INR1,589L; Q3 consolidated loss after tax INR728L. 28 Jan - Board approved Q3/9M FY26 unaudited results; exceptional labour-code charge INR1,589L; Q3 consolidated loss after tax INR728L.
3
Board Meeting Intimation for Board Meeting Intimation For Digicontent Limited To Be Held On Wednesday, 28Th January, 2026.
21 Jan - Board meeting 28 Jan to approve unaudited Q3/nine-month results ended 31 Dec 2025; trading window closed till 30 Jan. 21 Jan - Board meeting 28 Jan to approve unaudited Q3/nine-month results ended 31 Dec 2025; trading window closed till 30 Jan.
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Jan - Certificate under SEBI Reg 74(5) for quarter ended 31 Dec 2025 from KFin regarding dematerialisation. 7 Jan - Certificate under SEBI Reg 74(5) for quarter ended 31 Dec 2025 from KFin regarding dematerialisation.
5
Closure of Trading Window
27 Dec 2025 - Trading window closed from 31 Dec 2025 until 48 hours after UFRs for quarter/nine-months ending 31 Dec 2025. 27 Dec 2025 - Trading window closed from 31 Dec 2025 until 48 hours after UFRs for quarter/nine-months ending 31 Dec 2025.
Frequently Asked Questions about Ahlcon Parenterals
What does Ahlcon Parenterals (India) Ltd do?
Ahlcon Parenterals (India) manufactures and sells pharmaceutical preparations in India. It offers I.V. fluids, antimicrobial I.V. fluids, and eye/ear drops.
Where is Ahlcon Parenterals (India) Ltd (524448) listed?
Ahlcon Parenterals (India) Ltd trades under code 524448 on the BSE.
Which sector does Ahlcon Parenterals (India) Ltd belong to?
Ahlcon Parenterals (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Ahlcon Parenterals (India) manufactures and sells pharmaceutical preparations in India. It offers I.V. fluids, antimicrobial I.V. fluids, and eye/ear drops.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524448.md for Ahlcon Parenterals (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.